Oftalmol Zh.2009;5:64-69.
http://doi.org/10.31288/oftalmolzh200956469
MODERN ASPECTS OF IMMONOSUPPRESSIVE THRERAPY OF ENDOGENIC UVEITES
Zhaboedov D. G., Ivanova N. V., Kopaenko A. I.
Kyev, Ukraine
The paper presents data of modern studies on application of immunosuppressive therapy in the treatment of severe endogenic uveitis. The results of the treatment with modern immunosuppressants are analyzed: inhibitors of tumour necrosis factor, antibodies to cytokine receptors and interferon a2a.
References
1.Павлюченко К. П., Кравцова Н. В. Исследование роли свободнорадикальных соединений в патогенезе эндогенного увеита // Офтальмол. журн. — 2006. — № 1. — С. 44-49.
2.Савко В. В., Нарицына Н. И., Коновалова Н. В. Основные этиологические формы эндогенных увеитов: клиника, диагностика, лечение // Офтальмол. журн. — 2006. — № 1. — С. 58-62.
3.Катаргина Л. А., Архипова Л. Т. Увеиты: патогенетическая иммуносупрессивная терапия. — М., 2004. — 100 с.
4.Шевчук Н. Е., Мальханов В. Б., Зайнутдинова Г. X. Содержание сосудисто-эндотелиального фактора роста и популяции лимфоцитов в крови больных увеитами различной этиологии // Офтальмол. журн. — 2007. — № 5. — С. 23-27.
5.Accorinti M., Pirraglia M. P., Paroli M. P. et al. Infliximab treatment for ocular and extraocular manifestations of Behcet's disease // Jpn. J. Ophthalmol. — 2007. — Vol. 51. — P. 191-196.
6.Ardoin S. P., Kredich D., Rabinobich E. et al. Infliximab to treat chonic noninfectious uveitis in children: retrospective case with long-term follow-up // Am. J. Ophthalmol. — 2007. — Vol. 144. — P. 844-849.
7.Bezditko P. A., Vlasko H. V., Mukcha I. D. The comparative analysis of application of the inravitreal triamcinolone and disrosopan in the treatment of the patients with cho-rioretinitis // Abstract book of the Joint Congress of SOE/ AAO. — Veinna, Austria, 2007. — P. 227.
8.Biester S., Deuter C., Michels H. et al. Adalimumab in the therapy of uveitis in Childhood // Br. J. Ophthalmol. — 2007. — Vol. 91. — P. 319-324.
9.Bodaghi B., Gendron G., Weschler B. et al. Efficacy of interferon alpha in the treatment of refractory and sight threatening uveitis: a retrospective monocentric study of 45 patients // Br. J. Ophthalmol. — 2007. — Vol. 91. — P. 335-433.
10.Buggage R. R., Levy-Clarke G., Sen H. N. et al. Adouble-masked, randomized study to investigate the safety and efficacy of daclizumab to treat the ocular complications related to Behcet's disease // Ocul. Immunol. Inflamm. — 2007. — Vol. 15. — P. 63-70.
11.Cekmen M., Everklioglu C., Er H. et al. Vascular endo-thelial growth factor levels are increased and associated with disease activity in patients with Behcet's syndrome // Int. J. Derrmatol. — 2003. — Vol. 42, № 11. — P. 870875.
12.Cordoro Coma M., Sorbin L., Onal S., Foster C. S. Intravit-real bevacizumab for treatment of uveitic macular edema // Ophthalmology. — 2007. — Vol. 114 (8). — P. 1574-1579.
13.Delyfer M. N., Rougier M. B., Hubschman J. P. et al. Cy-tomegalovirus retinitis following intravitreal injection of triamcinolone: report of two cases //Acta Ophthalmol. Scand. — 2007. — Vol. 85. — P. 681-683.
14.Dev S., McCallum R. M., Jaffee G. J. Methotrexate treat-ment for sarcoid-associated panuveitis // Ophthalmology. — 1999. — Vol. 106. — P. 111.
15.Doycheva D., Deuter C., Stuebiger N. et al. Mycopheno-late mofetil in the treatment of uveitis in children // Br. J. Ophthalmol. — 2007. — Vol. 91. — P. 180-184.
16.Fine H. F., Baffi J., Reed G. F. Aqueous humor and plasma vascular endothelial growth factor in uveitis-associated cystoid macular edema // Am. J. Ophthal. — 2001. — Vol. 132, № 5. — P. 794-796.
17.Fonollosa A., Segura A., Giralt J., Garcia-Arumi J. Tu-berculous uveitis after treatment with etanercept // Graefes Arch. Clin. Exp. Ophthalmol. — 2007. — Vol. 245. — P. 1397-1399.
18.Foster C. S., Baer J. C., Raizman M. B. Therapeutic re-sponses tosystemic immunosuppressive chemotherapy agents in patients with Behcet's Disease // Basic and Clinical Aspect. — New York, Marcel Dekker, 1991. — P. 581588.
19.Foster C. S., Barret F. Cataract development and cataract surgery in patients with juvenile rheumatoid arthritis irido-cyclitis // Ophthalmology. — 1993. — Vol. 100. — P. 809-817.
20.Foster C. S., Vitale A. T. Diagnosis and treatment of uveitis // Philadelphia, W. B. Saunders. — 2002. — P. 177-214.
21.Gallagher M., Quinones K., Cervantes-Castaneda R. A. et al. Biological response modifier therapy for refractory childhood uveitis // Br. J. Ophthalmol. — 2007. — Vol. 91. — P. 1341-1344.
22.Galor A., Perez V. L., Hammel J. P., Lowder C. Y. Dif-ferential effectiveness of etanercept and infliximab in the treatment of ocular inflammation // Ophthalmology. — 2006. — Vol. 113. — P. 2317-2323.
23.Guenudry J., Wechsler B., Terrada C. et al. Long-term efficacy and safety of low-dose interferon alpha2a therapy in severe uveitis associated with Behcet disease // Am. J. Ophthalmol. — 2008. — Vol. 146, № 6. — P. 837-844.
24.Imrie F. R., Dick A. D. Biologics in the treatment of uveitis // Curr. Opin. Ophthalmol. — 2007. — Vol. 18. — P. 481-486.
25.Jap A., Chee S. P. Immunosuppressive therapy for ocular diseases // Curr. Opin. Ophthalmol. — 2008. — Vol. 19 (6). — P. 535-540.
26.Jonas J. B., Spandau U. H., Rensch F. et al. Infectious and noninfectious endophthalmitis after intravitreal beva-cizumab // J. Ocul. Pharmacol. Ther. — 2007. — Vol. 23 (3). — P. 240-242.
27.Jovanovic S., Vukosavljevic M., Stanojevic-Paovic A., Petrovic M. The effects of posterior subtenos's casule triamcinolone injection on macular edema in patients with uveitis // Abstracts book of Joint Congress of SOE/ AAO. — Vienna, Austria, 2007. — P. 229.
28.Kozak Y., Verwaerde C. Cytokines in immunotherapy of experimental uveitis // Int. Rev. Immunol. — 2002. — Vol. 21 (2-3). — P. 231-253.
29.Laomba M. S., Martin C. M., Chamond R. R. et al. Aqueous and serum interferon y, interleukin (IL) 2, IL-4 and IL-10 in patients with uveitis // Arch. Ophthamol. — 2000. — Vol. 118, № 6. — P. 768-782.
30.Lim L., Suhler E. B., Smith J. R. Biologic therapies for inflammatory eye disease // Clin. Experiment Ophthalmol. — 2006. — Vol. 34. — P. 365-374.
31.Mackensen F., Heinz C., Becker M. D., Heiligenhaus A. Intravitreal bevacizumab (avastin) as a tretament for re-fractory macular edema in patients with uveitis: a pilot study // Retina. — 2008. — № 28 (1). — P. 4145.
32.Mushtaq B., Saeed T., Situnayake R. D., Murray P. I. Adalimumab for sightthreatening uveitis in Behcet's disease // Eye. — 2007. — Vol. 21. — P. 824-825.
33.Niccoli L., Nannini C., Benucci M. et al. Long-term effi-cacy of infliximab inrefractory posterior uveitis of Behcet's disease: a 24-month follow-up study // Rheumatology. — 2007. — Vol. 46. — P. 1161-1164.
34.Nussenblatt R. B., Palestine A. G., Chan C. C. et al. Ran-domized, double-masked study of cyclosporine compared to prednisolone in the treatment of endogenous uveitis // Am. J. Ophthalmol. — 1991. — Vol. 112. — P. 38-146.
35.Nussenblatt R. B., Peterson J. S., Foster C. S. et al. Initial evaluation of subcutaneous daclizumab treatments for noninfectious uveitis: a multicenter noncomparative interventional case series // Ophthalmology. — 2005. — Vol. 112. — P. 764-770.
36.Ohno S., Nakamura S., Hori S. et al. Efficacy, safety, and pharmacokinetics of multiple administration of infiximab in Behcet's disease with refractory uveoretinitis // J. Rheumatol. — 2004. — Vol. 31. — P. 1362-1368.
37.Peter J. Mc Cluskey, Hamish M. A. Management of chronic uveitis // Br. Med. J. — 2000. — Vol. 320. — P. 555-558.
38.Pilli S., Kotsolis A., Spaide R. F. et al. Endophthalmitis associated with intravitreal antivascular endothelial growth factor therapy injections in an office setting // Am. J. Ophthalmol. — 2008. — Vol. 145 (5). — P. 879-882.
39.Plskova J., Greiner K., Forrester J. V. Interferon-alfa as an effective treatment for noninfectious posterior uveitis and papanuveitis // Am. J. Ophthalmol. — 2007. — Vol. 144. — P. 55-61.
40.Rothova A. Corticosteroids in uveitis // Ophthalmol. Clin. North. Am. — 2002. — Vol. 15 (3). — P. 389-394.
41.Saidel M. A., Berrern J., Margolis T. P. Cytomegalovi-rus retinitis after intravitrous triamcinolone in an immu-nocompetent patient // Am. J. Ophthalmol. — 2005. — Vol. 140. — P. 1141-1143.
42.Saurenmann R. K., Levin A. V., Rose J. B. et al. Tumour nectosis factor a inhibitors in the treatment of childhood uveitis // Rheumatology. — 2006. — Vol. 45. — P. 982-989.
43.Sfikakis P. P., Kaklaminis P. H., Elezoglou A. et al. Inflix-imab for recurrent, sightthreatening ocular inflammation in Adamantiades-Behcet's disease // Ann. Intern. Med. — 2004. — Vol. 140. — P. 404-406.
44.Sfikakis P. P., Markomichelakus N., Alpsoy E. et al. Anti-TNF therapy in the management of Behcet's disease: re-view and basis for recommendations // Rheumatology. — 2007. — Vol. 46. — P. 736-741.
45.Shah S. S., Lowder C. Y., Fox D. A. et al. Low-dose meth-otrexate therapy for ocular inflammatory disease // Oph-thalmology. — 1992. — Vol. 99. — P. 1419-1423.
46.Siepmann K., Huber M., Stubinger N. et al. Mycophe-nolate mofetil is a highly effective and safe immunosup-pressive agent for the treatment of uveitis: a retrospective analysis of 106 patients // Graefes Arch. Clin. Exp. Ophthalmol. — 2006. — Vol. 244. — P. 788-794.
47.Sobrin L., Huang J. J., Christen W. et al. Daclizumab for treatment of birdshot Chorioretinopathy // Arch. Oph-thalmol. — 2008. — Vol. 126. — P. 186-191.
48.Sobrin L., Kim E. C., Christen W. et al. Infiximab therapy for the treatment of refractory ocular inflammatory disease // Arch. Ophthalmol. — 2007. — Vol. 125. — P. 895-900.
49.Towler H. M. A., Lighman S. L., Forrester J. V. Combination low dose cyclysporine A and steroid therapy in chronic intraocular inflammation // Eye. — 1990. — Vol. 4. — P. 514-520.
50.Tynjala P., Lindhal P., Honkanen V. et al. Infliximab and etanercept in the treatment of chronic uveitis associated with refractory juvenile idiopatihc arthritis // Ann. Rheum. Dis. — 2007. — Vol. 66. — P. 548-550.
51.Vazquez-Cobian L. B., Flynn T., Lehman T. J. A. Adali-mumab therapy for childhood uveitis // J. Pedieat. — 2006. — Vol. 149. — P. 572-575.
52.Whitcup S. M., Salvo E. C., Nussenblatt R. B. Combined cyclosporine and corticosteroid therapy for sight-threatening uveitis in Behcet's disease // Am. J. Ophthalmol. — 1994. — Vol. 118. — P. 39-45.
53.Yazici J., Pazarli H., Barnes C. G. et al. A controlled trial of azathioprine in Behcet's syndrome // N. Engl. J. Med. — 1990. — Vol. 332. — P. 281-285.